ArticleJACC. Asia2026
The Effect of High-Density Lipoprotein on the Rheumatic Mitral Valve Calcification and Surgical Prognosis.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic heart disease remains the most common valvular heart disease in Asia and often leads to severe calcification of the valve leaflets. However, the causes of calcification and the factors influencing the prognosis of surgical patients are not yet clearly understood.
objectivesThis study aimed to explore the impact of plasma high-density lipoprotein (HDL) levels on the formation of rheumatic mitral valve calcification and the surgical prognosis.
methodsThis retrospective cohort study included 847 patients who underwent mitral valve surgery for rheumatic heart disease at the Beijing Anzhen Hospital from January 2016 to December 2022. Patients were divided into a high HDL group (n = 413) and a low HDL group (n = 434) based on preoperative HDL levels.
resultsAmong 847 surgical patients (median follow-up 44.1 months), Kaplan-Meier analysis revealed that the high HDL group had higher mid-term survival (P = 0.018) and lower major adverse cardiovascular events risk (P = 0.005). Multivariate Cox regression confirmed HDL as independent risk factor for major adverse cardiovascular events (HR: 0.370; 95% CI: 0.220-0.620; P < 0.001), whereas other traditional lipid markers, including low-density lipoprotein (HR: 0.82; 95% CI: 0.54-1.23; P = 0.328) and triglycerides (HR: 0.65; 95% CI: 0.38-1.10; P = 0.107), were not statistically significant. Logistic regression indicated HDL as a protective factor against mitral valve calcification (HR: 0.01; 95% CI: 0.000-0.300; P = 0.009). Restricted cubic splines indicated that Agatston scores decreased with rising HDL when <1.3 mmol/L (P for nonlinear = 0.05; P for overall = 0.014).
conclusionsThe findings suggest that higher preoperative HDL levels could be correlated with lighter valve calcification, enhanced mid-term survival rates, and a decreased risk of cardiovascular events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.